NEULASTIM 6 MG/0.6 ML PREF. SYRINGE

Pharmacology Pegfilgrastim stimulates the production maturation and activation of neutrophils and activates neutrophils to increase both their migration and cytotoxicity. Pegfilgrastim has a prolonged duration of effect relative to filgrastim and a reduced renal clearance. Indications Hematopoietic radiation injury syndrome (acute; Neulasta only): To increase survival in patients acutely exposed to myelosuppressive doses of radiation. Prevention of chemotherapy-induced neutropenia (Fulphila [pegfilgrastim-jmdb; biosimilar] and Neulasta): To decrease the incidence of infection (as manifested by febrile neutropenia) in patients with nonmyeloid malignancies receiving myelosuppressive cancer chemotherapy associated with a clinically significant incidence of febrile neutropenia. Limitation of use: Pegfilgrastim products are not indicated for mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplant.